scispace - formally typeset
D

Danielle Denis

Researcher at Merck & Co.

Publications -  47
Citations -  2556

Danielle Denis is an academic researcher from Merck & Co.. The author has contributed to research in topics: Receptor & Agonist. The author has an hindex of 25, co-authored 47 publications receiving 2447 citations.

Papers
More filters
Journal ArticleDOI

The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs.

TL;DR: Rec recombinant cell lines have been employed in radioligand binding assays to determine the equilibrium inhibitor constants of known prostanoid receptor ligands at these eight receptors, allowing, for the first time, an assessment of the affinity and selectivity of several novel compounds at the individual human prostate receptors.
Journal ArticleDOI

Distribution and regulation of cyclooxygenase-2 in carrageenan-induced inflammation.

TL;DR: It is suggested that multiple mechanisms regulate COX‐2 induction especially in the more severe model of acute inflammation, carrageenan‐induced paw ædema and mechanical hyperalgesia, which suggest the presence of a positive feedback loop mechanism.
Journal ArticleDOI

Immunolocalization of cyclooxygenase-2 in the macula densa of human elderly

TL;DR: To gain insight into the role of prostanoids in human kidney function, the distribution of cyclooxygenase (COX) 1 and COX‐2 by immunofluorescence and immunohistochemistry in human kidneys from adults of various age groups is examined.
Journal ArticleDOI

Structure-activity relationship of cinnamic acylsulfonamide analogues on the human EP3 prostanoid receptor.

TL;DR: The structure-activity relationship of the chemical series was conducted and several analogues displaying sub-nanomolar K(i) values at the EP3 receptor and micromolar activities at theEP1, EP2 and EP4 receptors were found.
Journal ArticleDOI

From indomethacin to a selective COX-2 inhibitor: Development of indolalkanoic acids as potent and selective cyclooxygenase-2 inhibitors

TL;DR: A series of potent and highly selective cyclooxygenase-2 inhibitors have been prepared by replacing the benzoyl group of indomethacin with a 4-bromobenzyl group and by extending the acetic acid side chain, showing anti-inflammatory activity in rats with no evidence of GI toxicity, even at high doses.